Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Boehringer Ingelheim
Cantor Fitzgerald
Chubb
Queensland Health
Chinese Patent Office
Harvard Business School
McKesson
Fish and Richardson

Generated: April 24, 2018

DrugPatentWatch Database Preview

MEXILETINE HYDROCHLORIDE Drug Profile

« Back to Dashboard

When do Mexiletine Hydrochloride patents expire, and when can generic versions of Mexiletine Hydrochloride launch?

Mexiletine Hydrochloride is a drug marketed by Idt Australia Ltd, Teva, and Watson Labs. and is included in four NDAs.

The generic ingredient in MEXILETINE HYDROCHLORIDE is mexiletine hydrochloride. There are five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the mexiletine hydrochloride profile page.
Drug patent expirations by year for MEXILETINE HYDROCHLORIDE
Pharmacology for MEXILETINE HYDROCHLORIDE
Drug ClassAntiarrhythmic
Medical Subject Heading (MeSH) Categories for MEXILETINE HYDROCHLORIDE
Synonyms for MEXILETINE HYDROCHLORIDE
(+-)-1-Methyl-2-(2,6-xylyloxy)ethylamine hydrochloride
(+)-(S)-Mexiletine Hydrochloride
(+)-Mexiletine Hydrochloride
(2S)-1-(2,6-Dimethylphenoxy)-2-propanamine Hydrochloride
1-(2,6-dimethylphenoxy)-2-amino-propane hydrochloride
1-(2,6-dimethylphenoxy)-2-amino-propane hydrochloride;
1-(2,6-Dimethylphenoxy)-2-aminopropane hydrochloride
1-(2,6-Dimethylphenoxy)-2-propanamine
1-(2,6-Dimethylphenoxy)-2-propanamine hydrochloride
1-(2,6-Dimethylphenoxy)-2-propanamine hydrochloride, 97%
1-(2,6-dimethylphenoxy)-2-propananmineHydrochloride
1-(2,6-Dimethylphenoxy)-2-propylamine Hydrochloride
1-(2,6-dimethylphenoxy)prop-2-ylamine, chloride
1-(2,6-dimethylphenoxy)propan-2-amine hydrochloride
1-(2,6-dimethylphenoxy)propan-2-amine;hydrochloride
1-(2,6-dimethylphenoxy)propan-2-aminhydrochlorid
1-(2,6-Xylyloxy)-2-aminopropane
1-(2,6-Xylyloxy)-2-aminopropane hydrochloride
1-METHYL-2-(2 6-XYLYLOXY)ETHYLAMMONIUM CHLORIDE
1-Methyl-2-(2,6-xylyloxy)ethylamine Hydrochloride
1-Methyl-2-(2,6-xylyloxy)ethylamine hydrochloride
1-Methyl-2-(2,6-xylyloxy)ethylammonium chloride
2-(2-aminopropoxy)-1,3-dimethylbenzene hydrochloride
2-Propanamine, 1-(2,6-dimethylphenoxy)-, hydrochloride
2-Propanamine, 1-(2,6-dimethylphenoxy)-, hydrochloride, (+-)-
31828-71-4 (Parent)
370M014
5370-01-4
59890P
AC-4260
AC-8240
AC1L2IE1
AC1Q3993
AC1Q3DIN
AK163494
AKOS009139802
AN-8177
ANW-41640
AS-13790
BC681107
CAS-5370-01-4
CCG-213246
CHEBI:6917
CHEMBL1200606
CPD000326711
CTK6A8839
D00639
DSSTox_CID_25783
DSSTox_GSID_45783
DSSTox_RID_81125
DTXSID2045783
EBD30089
EINECS 226-362-1
EN300-53944
Ethylamine, 1-methyl-2-(2,6-xylyloxy)-, hydrochloride
EU-0100784
FT-0082653
HMS1568B04
HY-A0093
I01-3629
J10321
Katen
KO 1173
Ko 1173 Cl
Ko 1173Cl
KO-1173 CL
KO-1173-Cl
KS-00000F9V
LP00784
LS-68258
M 2727
M-2016
M2040
MCULE-4507699259
Mexiletene hydrochloride
Mexiletine (hydrochloride)
Mexiletine HCL
Mexiletine hydrochloride (JP17/USP)
Mexiletine hydrochloride [USAN:JAN]
Mexiletine hydrochloride [USAN:USP:JAN]
Mexiletine hydrochloride, European Pharmacopoeia (EP) Reference Standard
Mexiletine hydrochloride, powder
Mexiletine hydrochloride, United States Pharmacopeia (USP) Reference Standard
Mexiletinehydrochloride
mexilitene
MEXILITENE HYDROCHLORIDE
Mexitil
Mexitil (TN)
MFCD00216024
MLS001056756
MLS002222239
MLS002548872
MolPort-003-666-510
NC00682
NCGC00015659-06
NCGC00015659-14
NCGC00094121-01
NCGC00094121-02
NCGC00094121-03
NCGC00094121-04
NCGC00261469-01
NFEIBWMZVIVJLQ-UHFFFAOYSA-N
NSC-758639
NSC758639
OR053139
OR344776
Pharmakon1600-01503929
Prestwick_666
Ritalmex
s4225
SAM002264606
SBB003392
SC-17488
SCHEMBL42226
SMR000326711
SPECTRUM1503929
SR-01000075986
SR-01000075986-1
ST083488
ST24048103
TL8000021
Tox21_111249
Tox21_111249_1
Tox21_111249_2
Tox21_500784
TR-019000
V0364
VA11290
W-105713

US Patents and Regulatory Information for MEXILETINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Idt Australia Ltd MEXILETINE HYDROCHLORIDE mexiletine hydrochloride CAPSULE;ORAL 074450-001 May 16, 1996 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs MEXILETINE HYDROCHLORIDE mexiletine hydrochloride CAPSULE;ORAL 074711-001 Feb 26, 1997 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Teva MEXILETINE HYDROCHLORIDE mexiletine hydrochloride CAPSULE;ORAL 074377-001 May 16, 1995 RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Watson Labs MEXILETINE HYDROCHLORIDE mexiletine hydrochloride CAPSULE;ORAL 074865-003 Apr 13, 1998 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Argus Health
Deloitte
Medtronic
Covington
Chinese Patent Office
Harvard Business School
Colorcon
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.